• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在布基纳法索，15 个月大的儿童接种伤寒结合疫苗后，体内产生了持久的抗-Vi IgG 和 IgA 抗体应答。

Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso.

机构信息

Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.

出版信息

J Pediatric Infect Dis Soc. 2023 Sep 27;12(9):513-518. doi: 10.1093/jpids/piad058.

DOI:10.1093/jpids/piad058
PMID:37589596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10533206/
Abstract

We assessed anti-Vi IgG/IgA responses to typhoid conjugate vaccine (TCV) in children enrolled in a double-blind randomized controlled, phase 2 trial in Burkina Faso. Anti-Vi IgG seroconversion and anti-Vi IgA titers were higher in TCV than control recipients at 30-35 months post-vaccination. TCV induces durable immunity in Burkinabe children vaccinated at 15 months.

摘要

我们评估了在布基纳法索开展的一项双盲随机对照 2 期临床试验中入组儿童的伤寒 Vi 多糖结合疫苗（TCV）的抗-Vi IgG/IgA 应答。在接种后 30-35 个月，TCV 组的抗-Vi IgG 血清转化率和抗-Vi IgA 滴度均高于对照组。在 15 个月龄时接种 TCV 的布基纳法索儿童可产生持久的免疫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74f4/10533206/50c07ea1ff22/piad058_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74f4/10533206/c152cf24a317/piad058_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74f4/10533206/50c07ea1ff22/piad058_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74f4/10533206/c152cf24a317/piad058_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74f4/10533206/50c07ea1ff22/piad058_fig2.jpg

相似文献

1
Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso.在布基纳法索，15 个月大的儿童接种伤寒结合疫苗后，体内产生了持久的抗-Vi IgG 和 IgA 抗体应答。
J Pediatric Infect Dis Soc. 2023 Sep 27;12(9):513-518. doi: 10.1093/jpids/piad058.
2
A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper.一项在布基纳法索瓦加杜古 2 岁以下儿童中进行的伤寒结合疫苗的 II 期、随机、双盲、对照安全性和免疫原性试验：方法学论文。
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S59-S66. doi: 10.1093/cid/ciy1104.
3
Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.在布基纳法索，15-23 月龄儿童同时接种 A 群脑膜炎球菌结合疫苗和麻疹-风疹联合疫苗与伤寒结合疫苗的安全性和免疫原性。
Int J Infect Dis. 2021 Jan;102:517-523. doi: 10.1016/j.ijid.2020.10.103. Epub 2020 Nov 8.
4
Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.在伤寒流行地区，健康婴儿、儿童和成人中 Vi 多糖-破伤风类毒素结合疫苗（Typbar-TCV）的安全性和免疫原性：一项多中心、2 队列、开放性、双盲、随机对照 3 期研究。
Clin Infect Dis. 2015 Aug 1;61(3):393-402. doi: 10.1093/cid/civ295. Epub 2015 Apr 13.
5
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.在布基纳法索，与常规 9 月龄接种程序同时接种 Vi 伤寒结合疫苗的安全性和免疫原性：一项随机对照 2 期试验。
Int J Infect Dis. 2021 Jul;108:465-472. doi: 10.1016/j.ijid.2021.05.061. Epub 2021 Jun 1.
6
The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.在健康印度成年人中，针对伤寒沙门氏菌和甲型副伤寒沙门氏菌的二价结合疫苗的安全性和免疫原性：一项 1 期、随机、主动对照、双盲试验。
Lancet. 2024 Apr 20;403(10436):1554-1562. doi: 10.1016/S0140-6736(24)00249-6. Epub 2024 Mar 28.
7
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.马拉维 9 月龄至 12 岁儿童中伤寒结合疫苗的安全性和免疫原性：一项双盲、随机对照试验的嵌套子研究。
Lancet Glob Health. 2022 Sep;10(9):e1326-e1335. doi: 10.1016/S2214-109X(22)00275-3.
8
Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.在 2 岁以下儿童进行基础免疫（含或不含加强免疫）后长达 7 年，Vi 多糖-破伤风类毒素结合疫苗（Typbar TCV®）的抗体应答持续存在。
Vaccine. 2021 Oct 29;39(45):6682-6690. doi: 10.1016/j.vaccine.2021.07.073. Epub 2021 Oct 5.
9
Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.在尼泊尔健康志愿者中 Vi-DT 伤寒结合疫苗的安全性和免疫原性：一项观察者盲法、主动对照、随机、非劣效性、3 期临床试验。
Lancet Infect Dis. 2022 Apr;22(4):529-540. doi: 10.1016/S1473-3099(21)00455-2. Epub 2021 Dec 20.
10
An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.一项开放性、对照、单次剂量、临床 I 期研究，旨在评估伤寒结合疫苗（Vi-CRM197）在菲律宾健康成年人中的安全性和免疫原性。
Vaccine. 2021 May 6;39(19):2620-2627. doi: 10.1016/j.vaccine.2021.03.089. Epub 2021 Apr 10.

引用本文的文献

1
Immunogenicity and reactogenicity of a booster dose of a typhoid conjugate vaccine (TCV) in Malawian pre-school children.一剂伤寒结合疫苗（TCV）加强针在马拉维学龄前儿童中的免疫原性和反应原性。
EClinicalMedicine. 2025 Feb 12;81:103100. doi: 10.1016/j.eclinm.2025.103100. eCollection 2025 Mar.
2
Genotypic Diversity among Typhi Isolated from Children Living in Informal Settlements in Nairobi, Kenya.从肯尼亚内罗毕非正规住区儿童中分离出的伤寒杆菌的基因型多样性
Int J Clin Microbiol. 2024;1(3):18-27. doi: 10.14302/issn.2690-4721.ijcm-24-5195. Epub 2024 Sep 16.
3
The use of controlled human infection models to identify correlates of protection for invasive vaccines.

本文引用的文献

1
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.马拉维 9 月龄至 12 岁儿童中伤寒结合疫苗的安全性和免疫原性：一项双盲、随机对照试验的嵌套子研究。
Lancet Glob Health. 2022 Sep;10(9):e1326-e1335. doi: 10.1016/S2214-109X(22)00275-3.
2
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.在尼泊尔进行的伤寒结合疫苗的有效性：3 期、随机、对照试验的最终结果。
Lancet Glob Health. 2021 Nov;9(11):e1561-e1568. doi: 10.1016/S2214-109X(21)00346-6.
3
Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
利用受控人体感染模型来确定侵袭性疫苗的保护相关因素。
Front Immunol. 2024 Aug 27;15:1457785. doi: 10.3389/fimmu.2024.1457785. eCollection 2024.
4
Longevity of immune response after a single dose of typhoid conjugate vaccine against Salmonella Typhi among children in Hyderabad, Pakistan.在巴基斯坦海得拉巴的儿童中，单剂量伤寒结合疫苗针对伤寒沙门氏菌的免疫反应持续时间。
Int J Infect Dis. 2024 Oct;147:107187. doi: 10.1016/j.ijid.2024.107187. Epub 2024 Jul 20.
在 2 岁以下儿童进行基础免疫（含或不含加强免疫）后长达 7 年，Vi 多糖-破伤风类毒素结合疫苗（Typbar TCV®）的抗体应答持续存在。
Vaccine. 2021 Oct 29;39(45):6682-6690. doi: 10.1016/j.vaccine.2021.07.073. Epub 2021 Oct 5.
4
Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.马拉维儿童伤寒疫苗的安全性和有效性。
N Engl J Med. 2021 Sep 16;385(12):1104-1115. doi: 10.1056/NEJMoa2035916.
5
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.在孟加拉国城市地区使用Vi-破伤风类毒素结合疫苗对儿童进行伤寒热疫苗接种的保护作用：一项整群随机试验。
Lancet. 2021 Aug 21;398(10301):675-684. doi: 10.1016/S0140-6736(21)01124-7. Epub 2021 Aug 9.
6
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.在布基纳法索，与常规 9 月龄接种程序同时接种 Vi 伤寒结合疫苗的安全性和免疫原性：一项随机对照 2 期试验。
Int J Infect Dis. 2021 Jul;108:465-472. doi: 10.1016/j.ijid.2021.05.061. Epub 2021 Jun 1.
7
Vi-specific serological correlates of protection for typhoid fever.伤寒血清学保护的 Vi 特异性相关因素。
J Exp Med. 2021 Feb 1;218(2). doi: 10.1084/jem.20201116.
8
Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.在布基纳法索，15-23 月龄儿童同时接种 A 群脑膜炎球菌结合疫苗和麻疹-风疹联合疫苗与伤寒结合疫苗的安全性和免疫原性。
Int J Infect Dis. 2021 Jan;102:517-523. doi: 10.1016/j.ijid.2020.10.103. Epub 2020 Nov 8.
9
IgA and IgG1 Specific to Vi Polysaccharide of Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model.血清型 Vi 多糖的 IgA 和 IgG1 特异性与伤寒感染人体模型中的保护状态相关。
Front Immunol. 2019 Nov 1;10:2582. doi: 10.3389/fimmu.2019.02582. eCollection 2019.
10
Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.采用伤寒沙门氏菌人体感染模型评估 Vi 结合破伤风类毒素疫苗在预防伤寒中的效果和免疫原性：一项随机对照、2b 期临床试验。
Lancet. 2017 Dec 2;390(10111):2472-2480. doi: 10.1016/S0140-6736(17)32149-9. Epub 2017 Sep 28.